Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Faster Aspart 200 U/mL · 1 trial · 1 indication
Measured in pmol\*h/L
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence: formulation D, faster aspart 100 U/mL, formulation B, formulation A, formulation C, formulation E. The dosing visits will be separated by wash-out periods (2-21 days). |
| Group B | EXPERIMENTAL | Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence: formulation C, formulation B, formulation D, formulation E, formulation A, faster aspart 100 U/mL. The dosing visits will be separated by wash-out periods (2-21 days). |
| Group C | EXPERIMENTAL | Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence: formulation E, formulation C, formulation A, formulation B, faster aspart 100 U/mL, formulation D. The dosing visits will be separated by wash-out periods (2-21 days). |
| Group D | EXPERIMENTAL | Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence: formulation A, formulation D, formulation C, faster aspart 100 U/mL, formulation E, formulation B. The dosing visits will be separated by wash-out periods (2-21 days). |
| Group E | EXPERIMENTAL | Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence: faster aspart 100 U/mL, formulation A, formulation E, formulation D, formulation B, formulation C. The dosing visits will be separated by wash-out periods (2-21 days). |
| Group F | EXPERIMENTAL | Participants will be allocated to a treatment sequence consisting of 5 formulations of faster aspart 200 U/mL and faster aspart 100 U/mL in following sequence: formulation B, formulation E, faster aspart 100 U/mL, formulation C, formulation D, formulation A. The dosing visits will be separated by wash-out periods (2-21 days). |
| Name | Type | Description |
|---|---|---|
| Faster Aspart 200 U/mL | DRUG | A single dose (0.15 U/kg) of five formulations of fast-acting insulin aspart 200 U/mL (formulations A, B, C, D, E) in a sequential manner via subcutaneous injection. |
| Faster aspart 100 U/mL | DRUG | A single dose (0.15 U/kg) of fast-acting insulin aspart 100 U/mL via subcutaneous injection. |
Inclusion Criteria: * Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent * Diagnosed with type 1 diabetes mellitus greater than or equal to 1 year prior to the day of screening * Treated with multiple daily insulin injections or continuous subcutaneous insulin...
Faster Aspart 200 U/mL is an investigational drug being studied for the treatment of Type 1 Diabetes Mellitus. It is a small molecule developed by Novo Nordisk A/S and is currently in Phase 1 clinical development. The drug is not yet approved and remains under investigation.
Faster Aspart 200 U/mL is developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The company is conducting clinical trials to evaluate the drug's effects in people with Type 1 Diabetes Mellitus.
Faster Aspart 200 U/mL is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
Faster Aspart 200 U/mL has one completed clinical trial, identified as NCT03723759. This Phase 1 study, titled 'A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus,' enrolled 56 participants in Germany.
Faster Aspart 200 U/mL is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial, NCT03723759, was a controlled, double-blind, randomized study involving 56 participants with Type 1 Diabetes Mellitus.